Denali Therapeutics Operating Expenses Growth & History (DNLI)
Denali Therapeutics's operating expenses was $555.3M for fiscal 2025.
View full Denali Therapeutics company overviewDenali Therapeutics annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $555.3M | $53.5M | +10.65% |
| 2024 | 2024-12-31 | $501.9M | −$25.4M | −4.81% |
| 2023 | 2023-12-31 | $527.2M | $78.0M | +17.37% |
| 2022 | 2022-12-31 | $449.2M | $104.8M | +30.43% |
| 2021 | 2021-12-31 | $344.4M | $71.5M | +26.19% |
| 2020 | 2020-12-31 | $272.9M | $33.1M | +13.79% |
| 2019 | 2019-12-31 | $239.9M | $64.3M | +36.65% |
| 2018 | 2018-12-31 | $175.5M | $85.4M | +94.73% |
| 2017 | 2017-12-31 | $90.1M | $2.7M | +3.10% |
| 2016 | 2016-12-31 | $87.4M | — | — |
Denali Therapeutics quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $134.1M | −$818,000 | −0.61% |
| Q1 2026 | 2026-03-31 | $137.4M | −$8.2M | −5.65% |
| Q4 2025 | 2025-12-31 | $137.4M | $7.5M | +5.79% |
| Q3 2025 | 2025-09-30 | $137.4M | $14.2M | +11.57% |
| Q2 2025 | 2025-06-30 | $135.0M | $18.4M | +15.76% |
| Q1 2025 | 2025-03-31 | $145.6M | $13.3M | +10.08% |
| Q4 2024 | 2024-12-31 | $129.8M | −$2.7M | −2.06% |
| Q3 2024 | 2024-09-30 | $123.2M | $8.1M | +7.06% |
| Q2 2024 | 2024-06-30 | $116.6M | −$7.0M | −5.70% |
| Q1 2024 | 2024-03-31 | $132.3M | −$23.7M | −15.20% |
| Q4 2023 | 2023-12-31 | $132.6M | $16.9M | +14.65% |
| Q3 2023 | 2023-09-30 | $115.1M | $4.0M | +3.62% |
| Q2 2023 | 2023-06-30 | $123.6M | $9.7M | +8.56% |
| Q1 2023 | 2023-03-31 | $156.0M | $47.3M | +43.55% |
| Q4 2022 | 2022-12-31 | $115.6M | $26.0M | +29.00% |
| Q3 2022 | 2022-09-30 | $111.0M | $20.2M | +22.19% |
| Q2 2022 | 2022-06-30 | $113.9M | $29.1M | +34.38% |
| Q1 2022 | 2022-03-31 | $108.6M | $29.5M | +37.27% |
| Q4 2021 | 2021-12-31 | $89.6M | $16.9M | +23.23% |
| Q3 2021 | 2021-09-30 | $90.9M | $21.4M | +30.74% |
| Q2 2021 | 2021-06-30 | $84.8M | $17.6M | +26.27% |
| Q1 2021 | 2021-03-31 | $79.1M | $15.6M | +24.50% |
| Q4 2020 | 2020-12-31 | $72.7M | $10.3M | +16.51% |
| Q3 2020 | 2020-09-30 | $69.5M | $5.8M | +9.02% |
| Q2 2020 | 2020-06-30 | $67.1M | $164,000 | +0.24% |
| Q1 2020 | 2020-03-31 | $63.6M | $16.9M | +36.09% |
| Q4 2019 | 2019-12-31 | $62.4M | $11.5M | +22.52% |
| Q3 2019 | 2019-09-30 | $63.8M | $24.6M | +62.82% |
| Q2 2019 | 2019-06-30 | $67.0M | $7.9M | +13.43% |
| Q1 2019 | 2019-03-31 | $46.7M | $20.3M | +77.02% |
| Q4 2018 | 2018-12-31 | $51.0M | $27.4M | +116.46% |
| Q3 2018 | 2018-09-30 | $39.2M | $16.9M | +75.70% |
| Q2 2018 | 2018-06-30 | $59.0M | $36.5M | +161.57% |
| Q1 2018 | 2018-03-31 | $26.4M | $4.6M | +21.36% |
| Q4 2017 | 2017-12-31 | $23.5M | — | — |
| Q3 2017 | 2017-09-30 | $22.3M | — | — |
| Q2 2017 | 2017-06-30 | $22.6M | — | — |
| Q1 2017 | 2017-03-31 | $21.7M | — | — |
Denali Therapeutics operating expenses trends
Over the last five fiscal years, Denali Therapeutics's operating expenses increased from $272.9M to $555.3M, a change of $282.4M. The latest reported quarter, Q2 2026, shows $134.1M.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Denali Therapeutics source filings ↗